James C. Greenwood

New reports indicate that drug prices are slowing compared to other healthcare costs.

Policies for patient access to life-saving therapies must keep pace with biomedical innovation.

Protecting intellectual property rights is vital to biopharmaceutical innovation.

Sound policies are needed to govern the substitution of interchangeable biologics.

Ties between the biotechnology industry and university research are crucial.

This month's BIO Convention will encourage needed conversations.

Supportive public policy is needed in order for innovation to flourish.

The BIO convention, and healthcare reform, could re-energize biotech.

To move from R&D to breakthrough drugs, biotech companies need policies that support innovation.

BIO supports recent Congressional action toward a 12-year data exclusivity period for innovators.

The president of BIO proposes the ingredients needed for industry growth.

The organizations' presidents discuss market exclusivity, approval processes, and pending legislation.